A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of GTX-11 in Healthy Subjects
Phase 1
Active, not recruiting
- Conditions
- Pulmonary fibrosisMedDRA version: 20.0Level: LLTClassification code: 10016660Term: Fibrosis pulmonary Class: 10038738MedDRA version: 21.1Level: PTClassification code: 10021240Term: Idiopathic pulmonary fibrosis Class: 100000004855MedDRA version: 21.0Level: PTClassification code: 10037383Term: Pulmonary fibrosis Class: 100000004855MedDRA version: 21.1Level: LLTClassification code: 10022619Term: Interstitial pulmonary fibrosis Class: 10038738Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- Registration Number
- CTIS2023-504426-19-00
- Lead Sponsor
- Gat Therapeutics S.L.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method